title: How I treat Langerhans cell histiocytosis.
abstract: "Langerhans cell histiocytosis" (LCH) describes a spectrum of clinical presentations ranging from a single bone lesion or trivial skin rash to an explosive disseminated disease. Regardless of clinical severity, LCH lesions share the common histology of CD1a(+)/CD207(+) dendritic cells with characteristic morphology among an inflammatory infiltrate. Despite historical uncertainty defining LCH as inflammatory vs neoplastic and incomplete understanding of mechanisms of pathogenesis, clinical outcomes have improved markedly over the past decades through cooperative randomized clinical trials based on empiric therapeutic strategies. Significant advances include recognition of high- and low-risk clinical groups defined by hematopoietic and/or hepatic involvement, and of the importance of optimal intensity and of duration of chemotherapy. Nevertheless, mortality of high-risk patients, disease recurrence, lack of robustly tested salvage strategies, and significant disease morbidity of both high- and low-risk patients remain challenges. Recent discovery of recurrent somatic mutations in mitogen-activated protein kinase pathway genes at critical stages of myeloid hematopoietic differentiation in LCH patients supports redefinition of the disease as a myeloproliferative disorder and provides opportunities to develop novel approaches to diagnosis and therapy.
authors.affiliation: Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX; and.
authors.forename: Carl E
authors.initials: CE
authors.lastname: Allen
authors.affiliation: Center for Cancer and Immunology Research, Children's Research Institute, Children's National Medical Center, Washington, DC.
authors.forename: Stephan
authors.identifier: http://orcid.org/0000-0003-2484-1456
authors.initials: S
authors.lastname: Ladisch
authors.affiliation: Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX; and.
authors.forename: Kenneth L
authors.initials: KL
authors.lastname: McClain
mesh_terms: D000227:Adenine Nucleotides / Q000627:therapeutic use; D000328:Adult; D001087:Arabinonucleosides / Q000627:therapeutic use; D000077866:Clofarabine; D003561:Cytarabine / Q000627:therapeutic use; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008171:Lung Diseases / Q000628:therapy; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D012871:Skin Diseases / Q000628:therapy; D020775:Thoracic Surgery, Video-Assisted; D014623:Vaginal Diseases / Q000628:therapy
chemical_list: D000227:Adenine Nucleotides; D001087:Arabinonucleosides; D003561:Cytarabine; D000077866:Clofarabine
references.citation: Blood. 2008 Mar 1;111(5):2556-62
references.pmid: 18089850
references.citation: Pediatr Blood Cancer. 2008 Jul;51(1):71-5
references.pmid: 18260117
references.citation: Pediatr Blood Cancer. 2008 Jul;51(1):76-81
references.pmid: 18266220
references.citation: Am J Surg Pathol. 2008 Apr;32(4):615-9
references.pmid: 18277880
references.citation: J Pediatr. 2008 Jul;153(1):127-32
references.pmid: 18571550
references.citation: Pediatr Blood Cancer. 2008 Nov;51(5):703-6
references.pmid: 18623218
references.citation: J Pediatr. 2008 Nov;153(5):700-5, 705.e1-2
references.pmid: 18589441
references.citation: Bone Marrow Transplant. 2008 Oct;42 Suppl 2:S47-50
references.pmid: 18978744
references.citation: Pediatr Blood Cancer. 2009 Jan;52(1):97-101
references.pmid: 18951435
references.citation: Arch Dis Child. 2009 May;94(5):376-80
references.pmid: 19060008
references.citation: Cancer. 2009 Sep 1;115(17):3842-7
references.pmid: 19472396
references.citation: J Clin Oncol. 2009 Sep 10;27(26):4392-7
references.pmid: 19652076
references.citation: Pediatr Blood Cancer. 2009 Dec 15;53(7):1271-6
references.pmid: 19731321
references.citation: CNS Neurol Disord Drug Targets. 2009 Nov;8(5):380-6
references.pmid: 19702569
references.citation: Pediatr Blood Cancer. 2010 Mar;54(3):416-23
references.pmid: 19908293
references.citation: Immunol Rev. 2010 Mar;234(1):55-75
references.pmid: 20193012
references.citation: J Immunol. 2010 Apr 15;184(8):4557-67
references.pmid: 20220088
references.citation: J Pediatr. 2010 Jun;156(6):873-81, 881.e1
references.pmid: 20434166
references.citation: Blood. 2010 Sep 16;116(11):1919-23
references.pmid: 20519626
references.citation: Nature. 2010 Sep 30;467(7315):596-9
references.pmid: 20823850
references.citation: Orphanet J Rare Dis. 2011;6:83
references.pmid: 22151964
references.citation: PLoS One. 2012;7(4):e33891
references.pmid: 22506009
references.citation: PLoS One. 2012;7(8):e43257
references.pmid: 22916233
references.citation: Blood. 2012 Sep 20;120(12):e28-34
references.pmid: 22859608
references.citation: Blood. 2012 Sep 27;120(13):2700-3
references.pmid: 22879539
references.citation: Am J Respir Crit Care Med. 2012 Nov 1;186(9):930-2
references.pmid: 23118088
references.citation: Curr Top Microbiol Immunol. 2012;355:83-98
references.pmid: 21818706
references.citation: Blood. 2013 Feb 28;121(9):1495-500
references.pmid: 23258922
references.citation: Eur J Cancer. 2013 May;49(7):1654-61
references.pmid: 23481513
references.citation: Pediatr Blood Cancer. 2013 Jun;60(6):E19-22
references.pmid: 23255383
references.citation: Melanoma Res. 2013 Jun;23(3):241
references.pmid: 23624369
references.citation: Orphanet J Rare Dis. 2013;8:72
references.pmid: 23672541
references.citation: Blood. 2013 Jun 20;121(25):5006-14
references.pmid: 23589673
references.citation: Pediatr Blood Cancer. 2013 Oct;60(10):1630-5
references.pmid: 23670879
references.citation: Adv Immunol. 2013;120:127-61
references.pmid: 24070383
references.citation: Pediatr Blood Cancer. 2014 Mar;61(3):479-87
references.pmid: 24106153
references.citation: J Exp Med. 2014 Apr 7;211(4):669-83
references.pmid: 24638167
references.citation: Blood. 2014 May 15;123(20):3152-5
references.pmid: 24652991
references.citation: Pediatr Blood Cancer. 2005 Jul;45(1):37-42
references.pmid: 15768381
references.citation: Bone Marrow Transplant. 2005 Aug;36(3):215-25
references.pmid: 15937510
references.citation: Eur J Cancer. 2005 Nov;41(17):2682-9
references.pmid: 16291085
references.citation: Pediatr Radiol. 2006 Oct;36(10):1105-7
references.pmid: 16819598
references.citation: Blood. 2014 Jul 24;124(4):483-92
references.pmid: 24850756
references.citation: Blood. 2014 Aug 14;124(7):1119-26
references.pmid: 24894769
references.citation: Blood. 2014 Sep 4;124(10):1655-8
references.pmid: 24982505
references.citation: Blood. 2014 Nov 6;124(19):3007-15
references.pmid: 25202140
references.citation: Am J Clin Oncol. 2014 Dec;37(6):592-6
references.pmid: 23466581
references.citation: Pediatr Blood Cancer. 2007 Oct 15;49(5):694-8
references.pmid: 17455318
references.citation: J Pediatr. 2014 Nov;165(5):990-6
references.pmid: 25441388
references.citation: Cancer Discov. 2015 Jan;5(1):64-71
references.pmid: 25324352
references.citation: Br J Haematol. 2015 Apr;169(2):299-301
references.pmid: 25400231
references.citation: Orphanet J Rare Dis. 2014;9:191
references.pmid: 25433492
references.citation: J Pediatr. 2001 May;138(5):728-34
references.pmid: 11343051
references.citation: Med Pediatr Oncol. 2001 Aug;37(2):108-14
references.pmid: 11496348
references.citation: Med Pediatr Oncol. 2002 Mar;38(3):178-82
references.pmid: 11836717
references.citation: Nature. 2002 Jun 27;417(6892):949-54
references.pmid: 12068308
references.citation: Blood. 2004 Feb 1;103(3):784-9
references.pmid: 14551141
references.citation: Pediatr Blood Cancer. 2004 May;42(5):438-44
references.pmid: 15049016
references.citation: Pediatr Blood Cancer. 2004 Jul;43(1):55-8
references.pmid: 15170890
references.citation: Pediatr Blood Cancer. 2004 Jul;43(1):59-65
references.pmid: 15170891
references.citation: Clin Chest Med. 2004 Sep;25(3):561-71, vii
references.pmid: 15331192
references.citation: Biomedicine. 1973 Sep;18(5):365-71
references.pmid: 4356601
references.citation: Skeletal Radiol. 1983;10(4):227-35
references.pmid: 6359441
references.citation: N Engl J Med. 1989 Oct 26;321(17):1157-62
references.pmid: 2797079
references.citation: Med Pediatr Oncol. 1989;17(6):492-5
references.pmid: 2685528
references.citation: Cancer. 1993 Feb 1;71(3):865-73
references.pmid: 8431870
references.citation: Med Pediatr Oncol. 1993;21(4):265-70
references.pmid: 8469221
references.citation: Med Pediatr Oncol. 1994;23(2):81-5
references.pmid: 8202046
references.citation: Med Pediatr Oncol. 1997 Jan;28(1):9-14
references.pmid: 8950330
references.citation: J Neurol Sci. 1997 Feb 12;145(2):205-11
references.pmid: 9094050
references.citation: Hematol Oncol Clin North Am. 1998 Apr;12(2):213-9
references.pmid: 9561896
references.citation: Hematol Oncol Clin North Am. 1998 Apr;12(2):369-78
references.pmid: 9561906
references.citation: Eur J Cancer. 1999 May;35(5):747-67; discussion 767-9
references.pmid: 10505036
references.citation: AMA Arch Pathol. 1953 Jul;56(1):84-102
references.pmid: 13057466
references.citation: Pediatr Dev Pathol. 2004 Nov-Dec;7(6):607-14
references.pmid: 15630529
references.citation: Trends Endocrinol Metab. 2007 Aug;18(6):252-7
references.pmid: 17600725
references.citation: Pediatr Blood Cancer. 2008 Jan;50(1):72-9
references.pmid: 17455311
references.citation: J Exp Med. 2007 Dec 24;204(13):3119-31
references.pmid: 18086861
references.citation: J Exp Med. 2007 Dec 24;204(13):3133-46
references.pmid: 18086862